SCHEMBL5732032

SCHEMBL5732032

CC(C)n1c(C=O)c(-c2ccc(F)cc2)c(-c2ccc(F)cc2)c1C(=O)OCc1ccccc1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MGLL Q99685 1/20 0.41
DHODH Q02127 1/20 0.40
HMGCR P04035 7/20 0.40
CYP2C9 P11712 3/20 0.40
SIRT6 Q8N6T7 2/20 0.40
ABCC3 O15438 1/20 0.40
ABCB11 O95342 1/20 0.40
PGR P06401 1/20 0.40
ADORA3 P0DMS8 1/20 0.40
RXRA P19793 1/20 0.40
TBXA2R P21731 1/20 0.40
CCKAR P32238 1/20 0.40
ADRA1A P35348 1/20 0.40
PTGS2 P35354 1/20 0.40
NR4A2 P43354 1/20 0.40
PDE4D Q08499 1/20 0.40
SLC10A1 Q14973 1/20 0.40
SLC6A2 P23975 1/20 0.40
SLC6A3 Q01959 1/20 0.40
KMT2A Q03164 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6091508 0.81 MEN1 (0.44) HMGCRCYP2C9SIRT6ABCC3ABCB11
SCHEMBL5732422 0.80 HMGCR (0.42) HMGCRCYP2C9SIRT6ABCC3ABCB11
SCHEMBL5732426 0.80 HMGCR (0.42) HMGCRCYP2C9SIRT6ABCC3ABCB11
SCHEMBL5732419 0.80 HMGCR (0.42) HMGCRCYP2C9SIRT6ABCC3ABCB11
SCHEMBL5731592 0.80 HMGCR (0.43) HMGCRCYP2C9SIRT6ABCC3ABCB11
SCHEMBL5731467 0.80 HMGCR (0.52) HMGCRCYP2C9SIRT6ABCC3ABCB11
SCHEMBL5732628 0.80 CYP2C9 (0.57) HMGCRCYP2C9SIRT6ABCC3ABCB11
SCHEMBL5732626 0.80 CYP2C9 (0.57) HMGCRCYP2C9SIRT6ABCC3ABCB11
SCHEMBL5732633 0.80 CYP2C9 (0.57) HMGCRCYP2C9SIRT6ABCC3ABCB11
SCHEMBL5732541 0.79 HMGCR (0.51) HMGCRMAPTLMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040048911-A1 1-phenyl imidazol-2-one biphenylmethyl compounds for treatment of circulatory disorders G. D. SEARLE & CO. 2004-03-11 US claimed
US-20020038035-A1 1-phenyl imidazol-2-one biphenylmethyl compounds for treatment of circulatory disorders G.D. SEARLE & CO. 2002-03-28 US claimed
EP-0690854-B1 1-PHENYL-IMIDAZOL-2-ONE BIPHENYLMETHYL COMPOUNDS FOR TREATMENT OF CIRCULATORY DISORDERS SEARLE & CO (US) 2000-07-12 EP claimed
EP-0978515-A2 1-(substituted phenyl)-4-biphenylmethyl-imidazol-2-one derivatives, their preparation and their use as angiotensin II antagonists G.D. SEARLE & CO. (US) 2000-02-09 EP claimed
EP-1691803-A1 N-ALKYL PYRROLES AS HMG-COA REDUCTASE INHIBITORS Warner-Lambert Company LLC (US) 2006-08-23 EP disclosed
US-20050154042-A1 N-alkyl pyrroles as HMG-CoA reductase inhibitors WARNER-LAMBERT COMPANY 2005-07-14 US disclosed
WO-2005056004-A1 N-ALKYL PYRROLES AS HMG-COA REDUCTASE INHIBITORS WARNER-LAMBERT COMPANY LLC (US) 2005-06-23 WO disclosed
US-6858636-B2 1-phenyl imidazol-2-one biphenylmethyl compounds for treatment of circulatory disorders G.D. SEARLE & CO. (US) 2005-02-22 US disclosed
US-20040048911-A1 1-phenyl imidazol-2-one biphenylmethyl compounds for treatment of circulatory disorders G. D. SEARLE & CO. 2004-03-11 US disclosed
US-6630497-B2 1-phenyl imidazol-2-one biphenylmethyl compounds for treatment of circulatory disorders G.D. SEARLE & CO 2003-10-07 US disclosed
US-20020038035-A1 1-phenyl imidazol-2-one biphenylmethyl compounds for treatment of circulatory disorders G.D. SEARLE & CO. 2002-03-28 US disclosed
EP-0690854-B1 1-PHENYL-IMIDAZOL-2-ONE BIPHENYLMETHYL COMPOUNDS FOR TREATMENT OF CIRCULATORY DISORDERS SEARLE & CO (US) 2000-07-12 EP disclosed
EP-0978515-A2 1-(substituted phenyl)-4-biphenylmethyl-imidazol-2-one derivatives, their preparation and their use as angiotensin II antagonists G.D. SEARLE & CO. (US) 2000-02-09 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020038035-A1 1-phenyl imidazol-2-one biphenylmethyl compounds for treatment of circulatory disorders AGTR1, AGTR2, REN MGLL 4806/4885DHODH 3181/4885HMGCR 366/4885
US-20050154042-A1 N-alkyl pyrroles as HMG-CoA reductase inhibitors HMGCR, DHCR7, CYP11A1 MGLL 198/4885DHODH 186/4885HMGCR 1/4885
US-20040048911-A1 1-phenyl imidazol-2-one biphenylmethyl compounds for treatment of circulatory disorders AGTR1, AGTR2, REN MGLL 4806/4885DHODH 3181/4885HMGCR 366/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.